secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sylvamo Corp (SLVM)
CIK:        0001856485
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001193125-23-039775
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 3.03, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sylvamo enters cooperation agreement with Atlas Holdings, adds two directors, terminates poison pill
--------------------------------------------------------------------------------

- Cooperation agreement with Atlas FRM LLC (largest shareholder) signed Feb 14, 2023, avoiding proxy fight.
- Appointed Karl Meyers and Mark Wilde as independent directors effective March 1, expanding board to 11.
- Sylvamo agreed to file a shelf registration within 30 days for Atlas to sell common shares.
- Rights plan (poison pill) terminated immediately on Feb 15, 2023; related Series A Preferred Stock eliminated.
- Atlas Group subject to standstill, voting commitments, and ownership-based board seat triggers until at least Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856485/000119312523039775/0001193125-23-039775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856485/000119312523039775/d411973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-039775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer